Abstract：
Intrahepatic cholangiocarcinoma is a rare type of cancer that is usually discovered at an advanced stage where surgical treatment is not an option. When compared to standard systemic therapy, transarterial chemoembolization (TACE) can provide a survival benefit to unresectable patients. Extrahepatic tumor spread is not rare, but cardiac involvement is an unusual complication.We present the case of a 56-year-old man with histologically proven intrahepatic cholangiocarcinoma. Oncologic risk factors include hepatitis B and liver cirrhosis. Being in an unresectable stage of the disease, three TACE procedures were performed. Partial response was achieved (according to RECIST) leading to a 16-month survival. However, disease progression was present, with unusual heart metastases.TACE can bring a survival benefit to unresectable cholangiocarcinoma patients. Defining the best disease stages in which TACE can be implemented and introducing it as part of standard treatment guidelines still presents a challenge.
摘要：
肝内胆管癌是一种罕见的癌症，通常在晚期发现，手术治疗不是一种选择。与标准的全身治疗相比，经肝动脉化疗栓塞术(TACE)可以为无法切除的患者提供生存获益.肝外肿瘤扩散并不罕见，但心脏受累是一种不寻常的并发症.我们介绍了一名56岁的男子，经组织学证实为肝内胆管癌。肿瘤危险因素包括乙型肝炎和肝硬化。处于疾病不可切除的阶段，进行了三次TACE手术.实现部分反应(根据RECIST),导致16个月的存活。然而,疾病进展存在，不寻常的心脏转移。TACE可以为不可切除的胆管癌患者带来生存益处。定义可以实施TACE的最佳疾病阶段并将其作为标准治疗指南的一部分引入仍然存在挑战。
